The Barostim device from CVRx continues to gain momentum as a go-to heart failure treatment. A free webinar is scheduled to examine the device's new CPT codes, which go into effect in 2026.
For years, imaging experts have predicted that CCTA may become the primary imaging modality for coronary artery disease and eliminate the need for invasive diagnostic catheterizations. That prediction is now coming true.
